Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05660447 · ClinicalTrials.gov registry record · Phase 2
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
A Phase 2 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, sponsored by Wills Eye.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05660447: Active Phase 2 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, sponsored by Wills Eye.
NCT05660447 is a Phase 2 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy that is active but no longer recruiting, run by Wills Eye. The registered enrollment target is 80 participants, below the 359-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05660447, a Phase 2 study of Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy, is active but no longer recruiting, sponsored by Wills Eye.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if a drug called netarsudil is safe and able to prevent the development of scar tissue after retinal detachment repair. Patients eligible for this study are those diagnosed with a rhegmatogenous retinal detachment deemed at high risk for scar tissue formation (a process called 'proliferative vitreoretinopathy').
Conditions Studied
Interventions
- DRUG Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA]
- DRUG Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Study Locations (1)
Pennsylvania
- Wills Eye Physicians - Mid Atlantic Retina - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 2 |
What the registry record for NCT05660447 still lists
NCT05660447 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 359-participant average among 3 other Rhegmatogenous Retinal Detachment trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Rhegmatogenous Retinal Detachment appearing as the primary indexed condition, and to 2 interventions - of which Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] is the first listed.
NCT05660447 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05660447 about?
NCT05660447 is a clinical study titled "A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR". The purpose of this study is to determine if a drug called netarsudil is safe and able to prevent the development of scar tissue after retinal detachment repair. Patients eligible for this study are those diagnosed with a rhegmatogenous retinal detachment deemed at high risk for scar tissue formatio...
What is the current status of trial NCT05660447?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2023-02-06. Estimated completion is 2025-01-31.
What conditions does trial NCT05660447 study?
This clinical trial studies the following conditions: Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy.
What interventions are being tested in trial NCT05660447?
The interventions under investigation include: Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] (DRUG), Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud (DRUG).
Who is sponsoring clinical trial NCT05660447?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05660447 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhegmatogenous Retinal Detachment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
RECRUITING · Phase 2
-
Dropless Pars Plana Vitrectomy Study
RECRUITING · Phase 4
-
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI